Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Soleno Therapeutics ( (SLNO) ) has shared an announcement.
On July 10, 2025, Soleno Therapeutics announced a public offering of 2,352,941 shares of its common stock priced at $85.00 per share, with the potential to raise $200 million in gross proceeds, or $230 million if additional shares are purchased. The funds are intended to support the commercialization of VYKAT XR, regulatory activities in the EU, and further R&D efforts. The offering is expected to close on July 11, 2025, subject to customary conditions, and is managed by Goldman Sachs and Guggenheim Securities.
The most recent analyst rating on (SLNO) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.
Spark’s Take on SLNO Stock
According to Spark, TipRanks’ AI Analyst, SLNO is a Underperform.
Soleno Therapeutics shows high risk due to its lack of revenue and reliance on external financing. However, it maintains a solid equity base and is experiencing positive technical momentum, suggesting speculative interest. The valuation is typical for an early-stage biotech, with potential upside reliant on successful R&D outcomes.
To see Spark’s full report on SLNO stock, click here.
More about Soleno Therapeutics
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of rare diseases. Their first commercial product, VYKAT XR, is an oral treatment for hyperphagia in individuals with Prader-Willi syndrome.
Average Trading Volume: 986,190
Technical Sentiment Signal: Buy
Current Market Cap: $4.46B
Learn more about SLNO stock on TipRanks’ Stock Analysis page.